PAUL KATZ: Open Payments
NPI 1629047154 · CECILTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$171 in 10 payments from 6 companies in 2025. Trend: 2023 $129 · 2024 $122 · 2025 $171
Food & beverage: $171
| Company | Payments | Amount |
|---|---|---|
| Orexo US, Inc. | 3 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
| ABBVIE INC. | 1 | $16 |
Products named: REXULTI, Zubsolv, CAPLYTA, XIFAXAN, UBRELVY.
Industry payments across MD — which companies pay providers there.
